Updated FDA Review Concludes That Use of Type 2 Diabetes Medicine Pioglitazone May Be Linked to an Increased Risk of Bladder Cancer

Date: 
December, 2016
December 12, 2016. The US Food and Drug Administration (FDA) has conducted an updated review of the type 2 diabetes medication pioglitazone and confirmed that this drug may be linked to an increased risk of bladder cancer. The labels of pioglitazone-containing drugs already provide warning information regarding bladder cancer risk; this labeling will be updated with information from the current FDA review. Click here for full article